CASE REPORT
From the hypertransaminasemia symptoms to the recognition of late-onset Pompe disease in a 12-year-old boy
 
More details
Hide details
1
Chair and Department of Paediatrics in Zabrze, Medical University of Silesia in Katowice, Poland
 
 
Submission date: 2021-06-23
 
 
Final revision date: 2021-08-02
 
 
Acceptance date: 2021-08-03
 
 
Publication date: 2021-09-29
 
 
Pediatr Pol 2021;96(3):220-222
 
KEYWORDS
TOPICS
ABSTRACT
The paper presents the case of a 12-year-old boy hospitalised due to persistent hypertransaminasemia of unknown origin, in whom rare metabolic disease – Pompe disease, was finally diagnosed. We discuss the possible symptoms and the diagnostic criteria for Pompe disease, as well as modern genetic methods of diagnosing. The importance of including this metabolic disease in differential diagnosis of hypertransaminasemia was underlined. The recombinant human α-glucosidase as the enzyme replacement therapy makes nowadays the early diagnosis of Pompe disease especially important.
REFERENCES (9)
1.
Meena NK, Raben N. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Biomolecules 2020; 10: 1339.
 
2.
Taverna S, Cammarata G, Colomba P, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY) 2020; 12: 15856-15874.
 
3.
Sawada T, Kido J, Nakamura K. Newborn Screening for Pompe Disease. Int J Neonatal Screen 2020; 6: 31.
 
4.
Filosto M, Todeschini A, Cotelli MS, et al. Non-muscle involvement in late-onset glycogenosis II. Acta Myol 2013; 32: 91-94.
 
5.
Tsai LK, Hwu WL, Lee NC, et al. Clinical features of Pompe disease with motor neuronopathy. Neuromuscul Disord 2019; 29: 903-906.
 
6.
Herzog A, Hartung R, Reuser AJ, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis 2012; 7: 35.
 
7.
Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med 2019; 7: 278.
 
8.
Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med 2019; 7: 291.
 
9.
Koeberl DD, Li S, Dai J, et al. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012; 105: 221-227.
 
Journals System - logo
Scroll to top